Atara Biotherapeutics, Inc.
clinical-stage biotechnology company
ATRA Nasdaq
SEC CIK 1604464 LEI 549300WBXUXZRE03MS38
Follow Atara Biotherapeutics
Weekly email: filings, results
Revenue, last quarter
$1.2M
−64.6% vs same quarter last year
Net income
−$2.2M
+48.2% vs same quarter last year
EPS, diluted
−$0.15
+53.1% vs same quarter last year
Operating cash flow
−$879K
+91% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $120.8M | $32.7M |
| FY24 | $128.9M | −$85.4M |
| FY23 | $8.6M | −$276.1M |
| FY22 | $63.6M | −$228.3M |
| FY21 | - | −$340.1M |
| FY20 | - | −$306.6M |
| FY19 | - | −$291M |
| FY18 | - | −$230.7M |
| FY17 | - | −$119.5M |
| FY16 | - | −$79M |
| FY15 | - | −$57.2M |
| FY14 | - | −$28M |
| FY13 | - | −$8.8M |
| FY12 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 29.7% | 27.1% |
| FY24 | −64.7% | −66.2% |
| FY23 | −3219.5% | −3220.9% |
| FY22 | −441.2% | −359.1% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$50.9M |
| FY24 | −$69M |
| FY23 | −$194.2M |
| FY22 | −$274.6M |
| FY21 | −$231.1M |
| FY20 | −$185.3M |
| FY19 | −$241.4M |
| FY18 | −$215.7M |
| FY17 | −$107.7M |
| FY16 | −$63M |
| FY15 | −$37.4M |
| FY14 | −$16.7M |
| FY13 | −$6M |
| FY12 | - |
- Atara Biotherapeutics
- Healthcare median
Show the numbers
| Year | Atara Biotherapeutics | Healthcare median |
|---|---|---|
| FY25 | 27.1% | −30.6% |
| FY24 | −66.2% | −47% |
| FY23 | −3220.9% | −58% |
| FY22 | −359.1% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |